Literature DB >> 11333928

Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.

R Burrer1, D Salmon-Ceron, S Richert, G Pancino, G Spiridon, S Haessig, V Roques, F Barre-Sinoussi, A M Aubertin, C Moog.   

Abstract

The factors present in serum and plasma samples of human immunodeficiency virus (HIV)-infected patients that are responsible for the neutralization of four HIV type 1 (HIV-1) primary isolates in vitro have been analyzed. Purification of immunoglobulins (Ig) by affinity chromatography showed that the activities were mostly attributable to IgG and less frequently to IgA. For two samples, we have shown that the high-level and broad-spectrum inhibitory activity was essentially caused by non-Ig factors interfering with the measurement of antibody-specific neutralizing activity.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11333928      PMCID： PMC114952          DOI： 10.1128/JVI.75.11.5421-5424.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  19 in total

1.  Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate.

Authors:  C Devito; J Hinkula; R Kaul; L Lopalco; J J Bwayo; F Plummer; M Clerici; K Broliden
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

2.  Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.

Authors:  E Beirnaert; P Nyambi; B Willems; L Heyndrickx; R Colebunders; W Janssens; G van der Groen
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

3.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.

Authors:  P Moja; C Tranchat; I Tchou; B Pozzetto; F Lucht; C Desgranges; C Genin
Journal:  J Infect Dis       Date:  2000-05-08       Impact factor: 5.226

5.  CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.

Authors:  S Le Borgne; M Février; C Callebaut; S P Lee; Y Rivière
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 6.  CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor.

Authors:  E Barker
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

7.  Analysis of serum and plasma beta chemokines in primary HIV infection (PHI).

Authors:  M S Malnati; G Tambussi; L Fischetti; M Algeri; F Veglia; B Capiluppi; A Lazzarin; P Lusso
Journal:  J Biol Regul Homeost Agents       Date:  2000 Jan-Mar       Impact factor: 1.711

8.  HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket.

Authors:  C Pastori; C Barassi; S Piconi; R Longhi; M L Villa; A G Siccardi; M Clerici; L Lopalco
Journal:  J Biol Regul Homeost Agents       Date:  2000 Jan-Mar       Impact factor: 1.711

9.  Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.

Authors:  C Spenlehauer; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins.

Authors:  P A Kozlowski; S Jackson
Journal:  AIDS Res Hum Retroviruses       Date:  1992-10       Impact factor: 2.205
View more
  14 in total

1.  Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.

Authors:  Vincent Holl; Maryse Peressin; Sylvie Schmidt; Thomas Decoville; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

2.  Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Authors:  M Medina-Ramírez; V Sánchez-Merino; S Sánchez-Palomino; A Merino-Mansilla; C B Ferreira; I Pérez; N González; A Alvarez; J M Alcocer-González; F García; J M Gatell; J Alcamí; E Yuste
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

3.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

4.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.

Authors:  Gülşen Özkaya Şahin; Fredrik Månsson; Angelica A Palm; Elzbieta Vincic; Zacarias da Silva; Patrik Medstrand; Hans Norrgren; Eva Maria Fenyö; Marianne Jansson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-11-21       Impact factor: 2.205

7.  Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.

Authors:  Neil C Sheppard; Sarah L Davies; Simon A Jeffs; Sueli M Vieira; Quentin J Sattentau
Journal:  Clin Vaccine Immunol       Date:  2006-12-13

8.  Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.

Authors:  Anuska Llano; Jorge Carrillo; Beatriz Mothe; Lidia Ruiz; Silvia Marfil; Elisabet García; Eloísa Yuste; Víctor Sánchez; Bonaventura Clotet; Julià Blanco; Christian Brander
Journal:  J Transl Med       Date:  2013-02-22       Impact factor: 5.531

9.  Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.

Authors:  Vincent Holl; Maryse Peressin; Christiane Moog
Journal:  Viruses       Date:  2009-12-15       Impact factor: 5.048

10.  A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

Authors:  Clarisse Lorin; Lucile Mollet; Frédéric Delebecque; Chantal Combredet; Bruno Hurtrel; Pierre Charneau; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.